3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
12
Phase 3
5
Phase 1/2
2
Phase NA
1
Phase 2/3
1
Phase 1
1
Status
Completed
16
Terminated
4
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
87
Cyclophosphamide
75
Nivolumab
55
Specimen Handling
49
fludarabine
48
Magnetic Resonance Spectroscopy
44
Carboplatin
42
Biopsy
39
Radiotherapy
32
fludarabine phosphate
29
Gemcitabine
28
venetoclax
27
Paclitaxel
27
atezolizumab
26
Ipilimumab
26
Cisplatin
23
Radiation
22
Dexamethasone
22
Radiosurgery
21
durvalumab
20
Rituximab
20
Lenalidomide
19
Temozolomide
17
Bevacizumab
17
Pemetrexed
16
130-nm albumin-bound paclitaxel
16
palbociclib
15
Decitabine
15
Cytarabine
15
ibrutinib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Active not recruiting
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05650879
2025-07-15
HER2
Enliven Therapeutics
Phase 1
Active not recruiting
198 enrolled